{"id":366939,"date":"2025-09-01T11:11:58","date_gmt":"2025-09-01T11:11:58","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-galapagos-nv\/"},"modified":"2025-09-01T11:11:58","modified_gmt":"2025-09-01T11:11:58","slug":"how-to-buy-galapagos-nv","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/","title":{"rendered":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-366939","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - GLPG Hisse Senedine Yat\u0131r\u0131m","h1_source":{"label":"H1","type":"text","formatted_value":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - GLPG Hisse Senedine Yat\u0131r\u0131m"},"description":"Galapagos NV (GLPG) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu yenilik\u00e7i biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Galapagos NV (GLPG) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu yenilik\u00e7i biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Keskin biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Galapagos NV (GLPG), h\u00fccre terapisi inovasyonunun heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Bu Bel\u00e7ikal\u0131 biyoteknoloji \u015firketi, \u00e7\u0131\u011f\u0131r a\u00e7an CAR-T terapileriyle kanser tedavisinde devrim yarat\u0131rken sa\u011flam bir bilan\u00e7o tutuyor. T\u0131bb\u0131n gelece\u011fine maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in, Galapagos NV (GLPG) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 anlamak, d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc b\u00fcy\u00fcme f\u0131rsatlar\u0131n\u0131n kap\u0131lar\u0131n\u0131 a\u00e7abilir.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin biyoteknolojiye yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Galapagos NV (GLPG), h\u00fccre terapisi inovasyonunun heyecan verici s\u0131n\u0131r\u0131n\u0131 temsil ediyor. Bu Bel\u00e7ikal\u0131 biyoteknoloji \u015firketi, \u00e7\u0131\u011f\u0131r a\u00e7an CAR-T terapileriyle kanser tedavisinde devrim yarat\u0131rken sa\u011flam bir bilan\u00e7o tutuyor. T\u0131bb\u0131n gelece\u011fine maruz kalmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in, Galapagos NV (GLPG) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 anlamak, d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc b\u00fcy\u00fcme f\u0131rsatlar\u0131n\u0131n kap\u0131lar\u0131n\u0131 a\u00e7abilir."},"body_html":"<h2>\ud83d\udcc8 GLPG Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>1 Eyl\u00fcl 2025 itibar\u0131yla, Galapagos NV (GLPG) NASDAQ borsas\u0131nda <strong>28,79 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. \u015eirket, kanser tedavisini yeniden tan\u0131mlayabilecek iddial\u0131 klinik geli\u015ftirme programlar\u0131 ile \u00f6nemli nakit rezervlerini dengelerken b\u00fcy\u00fcleyici bir d\u00f6neme\u00e7te bulunuyor.<\/p> <p><strong>Takviminize Not Edin: 22 Ekim 2025<\/strong><\/p> <p>Bu tarih, GLPG yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kritik bir d\u00f6n\u00fcm noktas\u0131d\u0131r. \u015eirket, 2025 \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve ge\u00e7mi\u015fteki \u00f6r\u00fcnt\u00fcler bu t\u00fcr olaylar etraf\u0131nda \u00f6nemli fiyat hareketleri oldu\u011funu g\u00f6stermektedir. \u00d6nceki kazan\u00e7 a\u00e7\u0131klamas\u0131 23 Temmuz 2025'te ger\u00e7ekle\u015fmi\u015f ve yeni CEO Henry Gosebruch y\u00f6netimindeki \u015firketin stratejik y\u00f6n\u00fc hakk\u0131nda \u00f6nemli bilgiler sunmu\u015ftur.<\/p> <p><strong>Kazan\u00e7 Etkisi Analizi: Son \u00d6r\u00fcnt\u00fcler<\/strong><\/p> <p>Son alt\u0131 b\u00fcy\u00fck kurumsal olaya bakt\u0131\u011f\u0131m\u0131zda, \u00f6nemli duyurular etraf\u0131nda belirgin bir volatilite \u00f6r\u00fcnt\u00fcs\u00fc g\u00f6r\u00fcyoruz:<\/p> <ul> <li><strong>23 Temmuz 2025<\/strong>: Yar\u0131 y\u0131l sonu\u00e7lar\u0131, 3,1 milyar \u20ac nakit pozisyonu - hisse senedi ilk belirsizlikten sonra istikrar kazand\u0131<\/li> <li><strong>May\u0131s 2025<\/strong>: CEO de\u011fi\u015fimi Henry Gosebruch'a - kademeli pozitif momentum olu\u015ftu<\/li> <li><strong>Nisan 2025<\/strong>: 1. \u00e7eyrek sonu\u00e7lar\u0131 ve stratejik ayr\u0131lma duyurusu - kar\u0131\u015f\u0131k piyasa tepkisi<\/li> <li><strong>\u015eubat 2025<\/strong>: FDA RMAT tan\u0131mlamas\u0131 s\u00f6ylentileri - spek\u00fclatif al\u0131m bask\u0131s\u0131<\/li> <li><strong>Ocak 2025<\/strong>: \u0130\u015f ayr\u0131lma plan\u0131 a\u00e7\u0131kland\u0131 - ilk \u015f\u00fcphecilik sonras\u0131 kabul<\/li> <li><strong>Kas\u0131m 2024<\/strong>: Klinik deneme g\u00fcncellemeleri - \u0131l\u0131ml\u0131 pozitif tepki<\/li> <\/ul> <p>\u00d6r\u00fcnt\u00fc, GLPG'nin <strong>etkinlik \u00f6ncesi volatilite<\/strong> ya\u015fad\u0131\u011f\u0131n\u0131 ve klinik ya da stratejik geli\u015fmelerin onaylanmas\u0131n\u0131n ard\u0131ndan kal\u0131c\u0131 y\u00f6nl\u00fc hareketler g\u00f6sterdi\u011fini ortaya koyuyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2> <p>GLPG hisseleri, son alt\u0131 ayda biyoteknoloji sekt\u00f6r\u00fc volatilitesi ve \u015firket \u00f6zelindeki geli\u015fmeleri yans\u0131tarak \u00f6nemli dalgalanmalar ya\u015fad\u0131:<\/p> <p><strong>Ocak-Mart 2025<\/strong>: 22-26 $ aras\u0131 i\u015flem aral\u0131\u011f\u0131<\/p> <ul> <li>Piyasa ayr\u0131lma duyurusunu sindirdi<\/li> <li>Stratejik y\u00f6n hakk\u0131nda belirsizlik<\/li> <li>Temkinli yat\u0131r\u0131mc\u0131 pozisyonlamas\u0131<\/li> <\/ul> <p><strong>Nisan-Haziran 2025<\/strong>: 28-31 $ aral\u0131\u011f\u0131na toparlanma<\/p> <ul> <li>Yeni liderlik atamalar\u0131 g\u00fcveni art\u0131rd\u0131<\/li> <li>Klinik ilerleme g\u00fcncellemeleri iyimserlik sa\u011flad\u0131<\/li> <li>Nakit pozisyonunun istikrar\u0131 yat\u0131r\u0131mc\u0131lar\u0131 rahatlatt\u0131<\/li> <\/ul> <p><strong>Temmuz-Eyl\u00fcl 2025<\/strong>: \u015eu an 28-30 $ aras\u0131 konsolidasyon<\/p> <ul> <li>Kazan\u00e7 a\u00e7\u0131kl\u0131\u011f\u0131 temel olu\u015fturdu<\/li> <li>Stratejik alternatiflerin de\u011ferlendirilmesi devam ediyor<\/li> <li>Teknik destek 28 $ civar\u0131nda kuruldu<\/li> <\/ul> <p>Genel alt\u0131 ayl\u0131k performans, sekt\u00f6r r\u00fczgarlar\u0131na ra\u011fmen dayan\u0131kl\u0131l\u0131k g\u00f6steriyor; hisse senedi temel de\u011ferini korurken piyasa \u015firketin d\u00f6n\u00fc\u015f\u00fcm stratejisini de\u011ferlendiriyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 32-36 $<br> Klinik kilometre ta\u015flar\u0131 ve ayr\u0131lma tamamlanmas\u0131na ba\u011fl\u0131 olarak, GLPG y\u00fcr\u00fctme riskleri azald\u0131k\u00e7a ve \u00fcr\u00fcn hatt\u0131 g\u00f6r\u00fcn\u00fcrl\u00fc\u011f\u00fc artt\u0131k\u00e7a \u0131l\u0131ml\u0131 bir de\u011fer art\u0131\u015f\u0131 g\u00f6rebilir.<\/p> <p><strong>2026 Projeksiyonu<\/strong>: 40-50 $<br> Potansiyel tetikleyiciler aras\u0131nda GLPG5101 i\u00e7in kritik denemelerin ba\u015flamas\u0131 ve olas\u0131 ortakl\u0131k duyurular\u0131 yer al\u0131yor. Ayr\u0131lma stratejisinin ba\u015far\u0131l\u0131 uygulanmas\u0131 \u00f6nemli de\u011fer a\u00e7\u0131l\u0131m\u0131 sa\u011flayabilir.<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 60-80 $<br> GLPG5101 d\u00fczenleyici onay al\u0131r ve ticari ba\u015far\u0131 g\u00f6sterirse, hisse senedi \u00f6nemli bir yeniden de\u011ferleme ya\u015fayabilir. Hematolojik malignitelerde piyasa penetrasyonu de\u011ferlemeyi art\u0131racakt\u0131r.<\/p> <p><strong>2030 Vizyonu<\/strong>: 100 $+<br> Uzun vadeli ba\u015far\u0131, \u00fcr\u00fcn hatt\u0131n\u0131n geni\u015flemesine, ek \u00fcr\u00fcn onaylar\u0131na ve merkezi olmayan CAR-T \u00fcretiminde potansiyel pazar liderli\u011fine ba\u011fl\u0131d\u0131r.<\/p> <p><strong>Karar<\/strong>: Y\u00fcksek risk tolerans\u0131na sahip uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in B\u0130R\u0130KT\u0130R\u0130N. Mevcut fiyat, nakit deste\u011fi ve \u00fcr\u00fcn hatt\u0131 opsiyonelli\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda cazip giri\u015f noktalar\u0131 sunuyor.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <p><strong>Dikkatle De\u011ferlendirilmesi Gereken Riskler<\/strong><\/p> <ul> <li><em>Klinik Geli\u015fim Belirsizli\u011fi<\/em>: Biyoteknoloji yat\u0131r\u0131mlar\u0131 klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131d\u0131r. Ba\u015far\u0131s\u0131z denemeler \u00f6nemli de\u011feri h\u0131zla silebilir.<\/li> <li><em>Y\u00fcr\u00fctme Riski<\/em>: \u015eirketin karma\u015f\u0131k ayr\u0131lma stratejisi, birden fazla alanda kusursuz uygulama gerektirir.<\/li> <li><em>D\u00fczenleyici Engeller<\/em>: FDA onaylar\u0131, \u00f6zellikle CAR-T gibi yenilik\u00e7i tedaviler i\u00e7in asla garanti de\u011fildir.<\/li> <li><em>Nakit T\u00fcketim Endi\u015feleri<\/em>: Mevcut g\u00fc\u00e7l\u00fc pozisyona ra\u011fmen, ila\u00e7 geli\u015ftirme kaynaklar\u0131 h\u0131zla t\u00fcketir ve geri d\u00f6n\u00fc\u015f garantisi yoktur.<\/li> <li><em>Piyasa Rekabeti<\/em>: Daha derin kaynaklara sahip b\u00fcy\u00fck ila\u00e7 \u015firketleri ayn\u0131 tedavi alanlar\u0131nda rekabet eder.<\/li> <\/ul> <p><strong>B\u00fcy\u00fcme \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p> <ul> <li><em>Sa\u011flam Bilan\u00e7o<\/em>: 3,1 milyar \u20ac nakit, benzersiz bir \u00e7al\u0131\u015fma alan\u0131 ve stratejik esneklik sa\u011flar (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/23\/3120592\/0\/en\/Galapagos-Reports-Half-Year-2025-Financial-Results-and-Provides-Second-Quarter-Business-Update.html\">2025 \u0130lk Yar\u0131 Sonu\u00e7lar\u0131<\/a>)<\/li> <li><em>\u00c7\u0131\u011f\u0131r A\u00e7an Teknoloji<\/em>: 7 g\u00fcnl\u00fck damar-damar \u00fcretim s\u00fcresi, CAR-T terapi teslimat\u0131n\u0131 devrimle\u015ftirebilir<\/li> <li><em>FDA Tan\u0131mas\u0131<\/em>: GLPG5101 i\u00e7in RMAT tan\u0131mlamas\u0131 bilimi do\u011frular ve h\u0131zland\u0131r\u0131lm\u0131\u015f yol sa\u011flar<\/li> <li><em>Deneyimli Liderlik<\/em>: Yeni CEO Henry Gosebruch, kan\u0131tlanm\u0131\u015f i\u015flem uzmanl\u0131\u011f\u0131 getiriyor<\/li> <li><em>Piyasa \u0130htiyac\u0131<\/em>: Mantle h\u00fccre lenfomas\u0131, s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleriyle y\u00fcksek kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7 temsil eder<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <p><strong>Ciddi \u00d6neriler:<\/strong><\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'inden fazlas\u0131n\u0131 GLPG gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong> - Tek seferlik b\u00fcy\u00fck al\u0131m yerine, zamanlama riskini azaltmak i\u00e7in d\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yap\u0131n<\/li> <li><strong>Uyar\u0131 Seviyeleri Belirleyin<\/strong> - Giri\u015f\/\u00e7\u0131k\u0131\u015f noktalar\u0131n\u0131 belirlemek i\u00e7in 25 $ (destek) ve 35 $ (diren\u00e7) fiyat uyar\u0131lar\u0131 koyun<\/li> <\/ol> <p><strong>Esprili Ger\u00e7eklik Kontrol\u00fc:<\/strong><br> \"GLPG gibi biyoteknoloji hisseleriyle ticaret yapmak, bir lunapark treni \u00fczerinde kalp ameliyat\u0131 yapmak gibidir - heyecan verici, potansiyel olarak \u00f6d\u00fcllendirici, ancak kalbi zay\u0131f olanlar veya kolayca hareket hastal\u0131\u011f\u0131na yakalananlar i\u00e7in de\u011fildir!\"<\/p> <h2>\u2705 Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul komisyon yap\u0131s\u0131 sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Potansiyel kaybetmeye haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>G\u00fcncel De\u011feri Ara\u015ft\u0131r\u0131n<\/td><td>Biyoteknoloji hisselerinin mevcut kazan\u00e7lara de\u011fil, gelecekteki potansiyele g\u00f6re i\u015flem g\u00f6rd\u00fc\u011f\u00fcn\u00fc anlay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Limit Emirleri Kullan\u0131n<\/td><td>Volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131 belirleyin<\/td><\/tr> <tr><td>5<\/td><td>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc \u0130zleyin<\/td><td>Biyoteknoloji maruziyetinizi risk tolerans s\u0131n\u0131rlar\u0131 i\u00e7inde tutun<\/td><\/tr> <tr><td>6<\/td><td>Klinik Takvim Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td><td>Yakla\u015fan deneme sonu\u00e7lar\u0131 ve d\u00fczenleyici kararlar\u0131 takip edin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7eyreklik G\u00fcncellemeleri \u0130nceleyin<\/td><td>Nakit pozisyonu ve t\u00fcketim oran\u0131 hakk\u0131nda bilgi sahibi olun<\/td><\/tr> <tr><td>8<\/td><td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td><td>Avantajl\u0131 muamele i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td><\/tr> <tr><td>9<\/td><td>Sekt\u00f6r \u0130\u00e7inde \u00c7e\u015fitlendirin<\/td><td>Risk da\u011f\u0131tmak i\u00e7in di\u011fer biyoteknoloji hisselerini de\u011ferlendirin<\/td><\/tr> <tr><td>10<\/td><td>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/td><td>K\u00e2r alma ve zarar durdurma seviyelerinizi \u00f6nceden bilin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>Biyoteknoloji ticaretinde denemek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, sekt\u00f6r\u00fcn \u00f6zellikleriyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> - Y\u00fcksek volatiliteye sahip hisselerde \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan denemek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong> - Tek belge KYC s\u00fcreci sayesinde k\u0131sa piyasa f\u0131rsatlar\u0131nda hemen i\u015flem yapabilirsiniz<\/li> <li><strong>Geni\u015f \u00c7ekim Se\u00e7enekleri<\/strong> - Klinik tetikleyiciler ger\u00e7ekle\u015fti\u011finde k\u00e2rlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim i\u00e7in \u00e7oklu y\u00f6ntemler<\/li> <\/ul> <p>Platformun esnekli\u011fi, haber kaynakl\u0131 volatilitenin hem risk hem de f\u0131rsat yaratt\u0131\u011f\u0131 GLPG gibi biyoteknoloji hisselerinin h\u0131zl\u0131 fiyat hareketlerini y\u00f6netmek i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Galapagos NV: Kav\u015fakta Bir Biyoteknoloji Yenilik\u00e7isi<\/h2> <p>Galapagos NV, biyoteknoloji d\u00f6n\u00fc\u015f\u00fcm\u00fcnde b\u00fcy\u00fcleyici bir vaka \u00e7al\u0131\u015fmas\u0131d\u0131r. \u015eirket, geleneksel k\u00fc\u00e7\u00fck molek\u00fcl geli\u015ftirmeden merkezi olmayan h\u00fccre terapisi \u00fcretiminde \u00f6nc\u00fc konuma evrilmi\u015ftir. Avrupa ve Amerika Birle\u015fik Devletleri'nde faaliyet g\u00f6steren Galapagos, onkoloji ve imm\u00fcnoloji tedavilerini ilerletmeye adanm\u0131\u015f yakla\u015f\u0131k 700 ki\u015fiyi istihdam etmektedir.<\/p> <p>\u015eirketin h\u00fccre terapisi i\u015finin stratejik de\u011ferlendirmesi, potansiyel sat\u0131\u015f se\u00e7enekleri dahil olmak \u00fczere biyoteknoloji end\u00fcstrisinin dinamik do\u011fas\u0131n\u0131 yans\u0131tmaktad\u0131r. Bu belirsizli\u011fe ra\u011fmen, devrim niteli\u011findeki 7 g\u00fcnl\u00fck CAR-T \u00fcretim teknolojisi, Galapagos'u kanser tedavisinde potansiyel bir bozucu olarak konumland\u0131rmaktad\u0131r.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Galapagos'un merkezi olmayan \u00fcretim platformu, damar-damar CAR-T terapilerini sadece yedi g\u00fcnde \u00fcretebilmektedir; bu, sekt\u00f6r standartlar\u0131n\u0131n \u00fc\u00e7 ila d\u00f6rt hafta oldu\u011fu d\u00fc\u015f\u00fcn\u00fcld\u00fc\u011f\u00fcnde b\u00fcy\u00fck bir at\u0131l\u0131md\u0131r. Bu bulu\u015f, kanser hastalar\u0131n\u0131n en ileri tedavilere eri\u015fimini k\u00f6kten de\u011fi\u015ftirebilir ve daha h\u0131zl\u0131 tedavi sunumu ile say\u0131s\u0131z hayat kurtarabilir.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 GLPG Hisse Analizi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>1 Eyl\u00fcl 2025 itibar\u0131yla, Galapagos NV (GLPG) NASDAQ borsas\u0131nda <strong>28,79 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. \u015eirket, kanser tedavisini yeniden tan\u0131mlayabilecek iddial\u0131 klinik geli\u015ftirme programlar\u0131 ile \u00f6nemli nakit rezervlerini dengelerken b\u00fcy\u00fcleyici bir d\u00f6neme\u00e7te bulunuyor.<\/p>\n<p><strong>Takviminize Not Edin: 22 Ekim 2025<\/strong><\/p>\n<p>Bu tarih, GLPG yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in kritik bir d\u00f6n\u00fcm noktas\u0131d\u0131r. \u015eirket, 2025 \u00fc\u00e7\u00fcnc\u00fc \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayacak ve ge\u00e7mi\u015fteki \u00f6r\u00fcnt\u00fcler bu t\u00fcr olaylar etraf\u0131nda \u00f6nemli fiyat hareketleri oldu\u011funu g\u00f6stermektedir. \u00d6nceki kazan\u00e7 a\u00e7\u0131klamas\u0131 23 Temmuz 2025&#8217;te ger\u00e7ekle\u015fmi\u015f ve yeni CEO Henry Gosebruch y\u00f6netimindeki \u015firketin stratejik y\u00f6n\u00fc hakk\u0131nda \u00f6nemli bilgiler sunmu\u015ftur.<\/p>\n<p><strong>Kazan\u00e7 Etkisi Analizi: Son \u00d6r\u00fcnt\u00fcler<\/strong><\/p>\n<p>Son alt\u0131 b\u00fcy\u00fck kurumsal olaya bakt\u0131\u011f\u0131m\u0131zda, \u00f6nemli duyurular etraf\u0131nda belirgin bir volatilite \u00f6r\u00fcnt\u00fcs\u00fc g\u00f6r\u00fcyoruz:<\/p>\n<ul>\n<li><strong>23 Temmuz 2025<\/strong>: Yar\u0131 y\u0131l sonu\u00e7lar\u0131, 3,1 milyar \u20ac nakit pozisyonu &#8211; hisse senedi ilk belirsizlikten sonra istikrar kazand\u0131<\/li>\n<li><strong>May\u0131s 2025<\/strong>: CEO de\u011fi\u015fimi Henry Gosebruch&#8217;a &#8211; kademeli pozitif momentum olu\u015ftu<\/li>\n<li><strong>Nisan 2025<\/strong>: 1. \u00e7eyrek sonu\u00e7lar\u0131 ve stratejik ayr\u0131lma duyurusu &#8211; kar\u0131\u015f\u0131k piyasa tepkisi<\/li>\n<li><strong>\u015eubat 2025<\/strong>: FDA RMAT tan\u0131mlamas\u0131 s\u00f6ylentileri &#8211; spek\u00fclatif al\u0131m bask\u0131s\u0131<\/li>\n<li><strong>Ocak 2025<\/strong>: \u0130\u015f ayr\u0131lma plan\u0131 a\u00e7\u0131kland\u0131 &#8211; ilk \u015f\u00fcphecilik sonras\u0131 kabul<\/li>\n<li><strong>Kas\u0131m 2024<\/strong>: Klinik deneme g\u00fcncellemeleri &#8211; \u0131l\u0131ml\u0131 pozitif tepki<\/li>\n<\/ul>\n<p>\u00d6r\u00fcnt\u00fc, GLPG&#8217;nin <strong>etkinlik \u00f6ncesi volatilite<\/strong> ya\u015fad\u0131\u011f\u0131n\u0131 ve klinik ya da stratejik geli\u015fmelerin onaylanmas\u0131n\u0131n ard\u0131ndan kal\u0131c\u0131 y\u00f6nl\u00fc hareketler g\u00f6sterdi\u011fini ortaya koyuyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2>\n<p>GLPG hisseleri, son alt\u0131 ayda biyoteknoloji sekt\u00f6r\u00fc volatilitesi ve \u015firket \u00f6zelindeki geli\u015fmeleri yans\u0131tarak \u00f6nemli dalgalanmalar ya\u015fad\u0131:<\/p>\n<p><strong>Ocak-Mart 2025<\/strong>: 22-26 $ aras\u0131 i\u015flem aral\u0131\u011f\u0131<\/p>\n<ul>\n<li>Piyasa ayr\u0131lma duyurusunu sindirdi<\/li>\n<li>Stratejik y\u00f6n hakk\u0131nda belirsizlik<\/li>\n<li>Temkinli yat\u0131r\u0131mc\u0131 pozisyonlamas\u0131<\/li>\n<\/ul>\n<p><strong>Nisan-Haziran 2025<\/strong>: 28-31 $ aral\u0131\u011f\u0131na toparlanma<\/p>\n<ul>\n<li>Yeni liderlik atamalar\u0131 g\u00fcveni art\u0131rd\u0131<\/li>\n<li>Klinik ilerleme g\u00fcncellemeleri iyimserlik sa\u011flad\u0131<\/li>\n<li>Nakit pozisyonunun istikrar\u0131 yat\u0131r\u0131mc\u0131lar\u0131 rahatlatt\u0131<\/li>\n<\/ul>\n<p><strong>Temmuz-Eyl\u00fcl 2025<\/strong>: \u015eu an 28-30 $ aras\u0131 konsolidasyon<\/p>\n<ul>\n<li>Kazan\u00e7 a\u00e7\u0131kl\u0131\u011f\u0131 temel olu\u015fturdu<\/li>\n<li>Stratejik alternatiflerin de\u011ferlendirilmesi devam ediyor<\/li>\n<li>Teknik destek 28 $ civar\u0131nda kuruldu<\/li>\n<\/ul>\n<p>Genel alt\u0131 ayl\u0131k performans, sekt\u00f6r r\u00fczgarlar\u0131na ra\u011fmen dayan\u0131kl\u0131l\u0131k g\u00f6steriyor; hisse senedi temel de\u011ferini korurken piyasa \u015firketin d\u00f6n\u00fc\u015f\u00fcm stratejisini de\u011ferlendiriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 32-36 $<br \/> Klinik kilometre ta\u015flar\u0131 ve ayr\u0131lma tamamlanmas\u0131na ba\u011fl\u0131 olarak, GLPG y\u00fcr\u00fctme riskleri azald\u0131k\u00e7a ve \u00fcr\u00fcn hatt\u0131 g\u00f6r\u00fcn\u00fcrl\u00fc\u011f\u00fc artt\u0131k\u00e7a \u0131l\u0131ml\u0131 bir de\u011fer art\u0131\u015f\u0131 g\u00f6rebilir.<\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 40-50 $<br \/> Potansiyel tetikleyiciler aras\u0131nda GLPG5101 i\u00e7in kritik denemelerin ba\u015flamas\u0131 ve olas\u0131 ortakl\u0131k duyurular\u0131 yer al\u0131yor. Ayr\u0131lma stratejisinin ba\u015far\u0131l\u0131 uygulanmas\u0131 \u00f6nemli de\u011fer a\u00e7\u0131l\u0131m\u0131 sa\u011flayabilir.<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 60-80 $<br \/> GLPG5101 d\u00fczenleyici onay al\u0131r ve ticari ba\u015far\u0131 g\u00f6sterirse, hisse senedi \u00f6nemli bir yeniden de\u011ferleme ya\u015fayabilir. Hematolojik malignitelerde piyasa penetrasyonu de\u011ferlemeyi art\u0131racakt\u0131r.<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 100 $+<br \/> Uzun vadeli ba\u015far\u0131, \u00fcr\u00fcn hatt\u0131n\u0131n geni\u015flemesine, ek \u00fcr\u00fcn onaylar\u0131na ve merkezi olmayan CAR-T \u00fcretiminde potansiyel pazar liderli\u011fine ba\u011fl\u0131d\u0131r.<\/p>\n<p><strong>Karar<\/strong>: Y\u00fcksek risk tolerans\u0131na sahip uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in B\u0130R\u0130KT\u0130R\u0130N. Mevcut fiyat, nakit deste\u011fi ve \u00fcr\u00fcn hatt\u0131 opsiyonelli\u011fi g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda cazip giri\u015f noktalar\u0131 sunuyor.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<p><strong>Dikkatle De\u011ferlendirilmesi Gereken Riskler<\/strong><\/p>\n<ul>\n<li><em>Klinik Geli\u015fim Belirsizli\u011fi<\/em>: Biyoteknoloji yat\u0131r\u0131mlar\u0131 klinik deneme sonu\u00e7lar\u0131na ba\u011fl\u0131d\u0131r. Ba\u015far\u0131s\u0131z denemeler \u00f6nemli de\u011feri h\u0131zla silebilir.<\/li>\n<li><em>Y\u00fcr\u00fctme Riski<\/em>: \u015eirketin karma\u015f\u0131k ayr\u0131lma stratejisi, birden fazla alanda kusursuz uygulama gerektirir.<\/li>\n<li><em>D\u00fczenleyici Engeller<\/em>: FDA onaylar\u0131, \u00f6zellikle CAR-T gibi yenilik\u00e7i tedaviler i\u00e7in asla garanti de\u011fildir.<\/li>\n<li><em>Nakit T\u00fcketim Endi\u015feleri<\/em>: Mevcut g\u00fc\u00e7l\u00fc pozisyona ra\u011fmen, ila\u00e7 geli\u015ftirme kaynaklar\u0131 h\u0131zla t\u00fcketir ve geri d\u00f6n\u00fc\u015f garantisi yoktur.<\/li>\n<li><em>Piyasa Rekabeti<\/em>: Daha derin kaynaklara sahip b\u00fcy\u00fck ila\u00e7 \u015firketleri ayn\u0131 tedavi alanlar\u0131nda rekabet eder.<\/li>\n<\/ul>\n<p><strong>B\u00fcy\u00fcme \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p>\n<ul>\n<li><em>Sa\u011flam Bilan\u00e7o<\/em>: 3,1 milyar \u20ac nakit, benzersiz bir \u00e7al\u0131\u015fma alan\u0131 ve stratejik esneklik sa\u011flar (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/23\/3120592\/0\/en\/Galapagos-Reports-Half-Year-2025-Financial-Results-and-Provides-Second-Quarter-Business-Update.html\">2025 \u0130lk Yar\u0131 Sonu\u00e7lar\u0131<\/a>)<\/li>\n<li><em>\u00c7\u0131\u011f\u0131r A\u00e7an Teknoloji<\/em>: 7 g\u00fcnl\u00fck damar-damar \u00fcretim s\u00fcresi, CAR-T terapi teslimat\u0131n\u0131 devrimle\u015ftirebilir<\/li>\n<li><em>FDA Tan\u0131mas\u0131<\/em>: GLPG5101 i\u00e7in RMAT tan\u0131mlamas\u0131 bilimi do\u011frular ve h\u0131zland\u0131r\u0131lm\u0131\u015f yol sa\u011flar<\/li>\n<li><em>Deneyimli Liderlik<\/em>: Yeni CEO Henry Gosebruch, kan\u0131tlanm\u0131\u015f i\u015flem uzmanl\u0131\u011f\u0131 getiriyor<\/li>\n<li><em>Piyasa \u0130htiyac\u0131<\/em>: Mantle h\u00fccre lenfomas\u0131, s\u0131n\u0131rl\u0131 tedavi se\u00e7enekleriyle y\u00fcksek kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiya\u00e7 temsil eder<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<p><strong>Ciddi \u00d6neriler:<\/strong><\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;inden fazlas\u0131n\u0131 GLPG gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong> &#8211; Tek seferlik b\u00fcy\u00fck al\u0131m yerine, zamanlama riskini azaltmak i\u00e7in d\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yap\u0131n<\/li>\n<li><strong>Uyar\u0131 Seviyeleri Belirleyin<\/strong> &#8211; Giri\u015f\/\u00e7\u0131k\u0131\u015f noktalar\u0131n\u0131 belirlemek i\u00e7in 25 $ (destek) ve 35 $ (diren\u00e7) fiyat uyar\u0131lar\u0131 koyun<\/li>\n<\/ol>\n<p><strong>Esprili Ger\u00e7eklik Kontrol\u00fc:<\/strong><br \/> &#8220;GLPG gibi biyoteknoloji hisseleriyle ticaret yapmak, bir lunapark treni \u00fczerinde kalp ameliyat\u0131 yapmak gibidir &#8211; heyecan verici, potansiyel olarak \u00f6d\u00fcllendirici, ancak kalbi zay\u0131f olanlar veya kolayca hareket hastal\u0131\u011f\u0131na yakalananlar i\u00e7in de\u011fildir!&#8221;<\/p>\n<h2>\u2705 Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul komisyon yap\u0131s\u0131 sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Potansiyel kaybetmeye haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>G\u00fcncel De\u011feri Ara\u015ft\u0131r\u0131n<\/td>\n<td>Biyoteknoloji hisselerinin mevcut kazan\u00e7lara de\u011fil, gelecekteki potansiyele g\u00f6re i\u015flem g\u00f6rd\u00fc\u011f\u00fcn\u00fc anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Limit Emirleri Kullan\u0131n<\/td>\n<td>Volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Pozisyon B\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc \u0130zleyin<\/td>\n<td>Biyoteknoloji maruziyetinizi risk tolerans s\u0131n\u0131rlar\u0131 i\u00e7inde tutun<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Klinik Takvim Uyar\u0131lar\u0131 Ayarlay\u0131n<\/td>\n<td>Yakla\u015fan deneme sonu\u00e7lar\u0131 ve d\u00fczenleyici kararlar\u0131 takip edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7eyreklik G\u00fcncellemeleri \u0130nceleyin<\/td>\n<td>Nakit pozisyonu ve t\u00fcketim oran\u0131 hakk\u0131nda bilgi sahibi olun<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td>\n<td>Avantajl\u0131 muamele i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Sekt\u00f6r \u0130\u00e7inde \u00c7e\u015fitlendirin<\/td>\n<td>Risk da\u011f\u0131tmak i\u00e7in di\u011fer biyoteknoloji hisselerini de\u011ferlendirin<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejisi Belirleyin<\/td>\n<td>K\u00e2r alma ve zarar durdurma seviyelerinizi \u00f6nceden bilin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>Biyoteknoloji ticaretinde denemek isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option, sekt\u00f6r\u00fcn \u00f6zellikleriyle m\u00fckemmel uyum sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> &#8211; Y\u00fcksek volatiliteye sahip hisselerde \u00f6nemli sermaye taahh\u00fcd\u00fc olmadan denemek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong> &#8211; Tek belge KYC s\u00fcreci sayesinde k\u0131sa piyasa f\u0131rsatlar\u0131nda hemen i\u015flem yapabilirsiniz<\/li>\n<li><strong>Geni\u015f \u00c7ekim Se\u00e7enekleri<\/strong> &#8211; Klinik tetikleyiciler ger\u00e7ekle\u015fti\u011finde k\u00e2rlar\u0131n\u0131za h\u0131zl\u0131 eri\u015fim i\u00e7in \u00e7oklu y\u00f6ntemler<\/li>\n<\/ul>\n<p>Platformun esnekli\u011fi, haber kaynakl\u0131 volatilitenin hem risk hem de f\u0131rsat yaratt\u0131\u011f\u0131 GLPG gibi biyoteknoloji hisselerinin h\u0131zl\u0131 fiyat hareketlerini y\u00f6netmek i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Galapagos NV: Kav\u015fakta Bir Biyoteknoloji Yenilik\u00e7isi<\/h2>\n<p>Galapagos NV, biyoteknoloji d\u00f6n\u00fc\u015f\u00fcm\u00fcnde b\u00fcy\u00fcleyici bir vaka \u00e7al\u0131\u015fmas\u0131d\u0131r. \u015eirket, geleneksel k\u00fc\u00e7\u00fck molek\u00fcl geli\u015ftirmeden merkezi olmayan h\u00fccre terapisi \u00fcretiminde \u00f6nc\u00fc konuma evrilmi\u015ftir. Avrupa ve Amerika Birle\u015fik Devletleri&#8217;nde faaliyet g\u00f6steren Galapagos, onkoloji ve imm\u00fcnoloji tedavilerini ilerletmeye adanm\u0131\u015f yakla\u015f\u0131k 700 ki\u015fiyi istihdam etmektedir.<\/p>\n<p>\u015eirketin h\u00fccre terapisi i\u015finin stratejik de\u011ferlendirmesi, potansiyel sat\u0131\u015f se\u00e7enekleri dahil olmak \u00fczere biyoteknoloji end\u00fcstrisinin dinamik do\u011fas\u0131n\u0131 yans\u0131tmaktad\u0131r. Bu belirsizli\u011fe ra\u011fmen, devrim niteli\u011findeki 7 g\u00fcnl\u00fck CAR-T \u00fcretim teknolojisi, Galapagos&#8217;u kanser tedavisinde potansiyel bir bozucu olarak konumland\u0131rmaktad\u0131r.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Galapagos&#8217;un merkezi olmayan \u00fcretim platformu, damar-damar CAR-T terapilerini sadece yedi g\u00fcnde \u00fcretebilmektedir; bu, sekt\u00f6r standartlar\u0131n\u0131n \u00fc\u00e7 ila d\u00f6rt hafta oldu\u011fu d\u00fc\u015f\u00fcn\u00fcld\u00fc\u011f\u00fcnde b\u00fcy\u00fck bir at\u0131l\u0131md\u0131r. Bu bulu\u015f, kanser hastalar\u0131n\u0131n en ileri tedavilere eri\u015fimini k\u00f6kten de\u011fi\u015ftirebilir ve daha h\u0131zl\u0131 tedavi sunumu ile say\u0131s\u0131z hayat kurtarabilir.<\/p>\n"},"faq":[{"question":"Galapagos NV (GLPG) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"GLPG hisselerini sat\u0131n almak i\u00e7in NASDAQ eri\u015fimi sunan bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, g\u00fcncel fiyatlar\u0131 ara\u015ft\u0131r\u0131n ve limit emirleri kullanarak al\u0131m yap\u0131n. Ayr\u0131ca, klinik takvim ve piyasa haberlerini takip etmek \u00f6nemlidir."},{"question":"GLPG hisselerinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme sonu\u00e7lar\u0131n\u0131n belirsizli\u011fi, karma\u015f\u0131k ayr\u0131lma stratejisinin y\u00fcr\u00fct\u00fclmesi, d\u00fczenleyici onaylar\u0131n garantisizli\u011fi, nakit t\u00fcketimi ve piyasa rekabeti yer almaktad\u0131r."},{"question":"GLPG hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 32-36 $, 2026'da 40-50 $, 2028'de 60-80 $ ve 2030'da 100 $ \u00fczeri hedeflenmektedir. Bu tahminler klinik geli\u015fmeler ve stratejik uygulamalara ba\u011fl\u0131d\u0131r."},{"question":"Yeni ba\u015flayanlar GLPG hisseleriyle nas\u0131l i\u015flem yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, d\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yap\u0131n, fiyat uyar\u0131lar\u0131 belirleyin ve risk tolerans\u0131n\u0131za uygun pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc koruyun."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve geni\u015f \u00e7ekim se\u00e7enekleri sunarak, y\u00fcksek volatiliteye sahip biyoteknoloji hisselerinde esnek ve h\u0131zl\u0131 i\u015flem yapma imkan\u0131 sa\u011flar."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Galapagos NV (GLPG) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"GLPG hisselerini sat\u0131n almak i\u00e7in NASDAQ eri\u015fimi sunan bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, g\u00fcncel fiyatlar\u0131 ara\u015ft\u0131r\u0131n ve limit emirleri kullanarak al\u0131m yap\u0131n. Ayr\u0131ca, klinik takvim ve piyasa haberlerini takip etmek \u00f6nemlidir."},{"question":"GLPG hisselerinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme sonu\u00e7lar\u0131n\u0131n belirsizli\u011fi, karma\u015f\u0131k ayr\u0131lma stratejisinin y\u00fcr\u00fct\u00fclmesi, d\u00fczenleyici onaylar\u0131n garantisizli\u011fi, nakit t\u00fcketimi ve piyasa rekabeti yer almaktad\u0131r."},{"question":"GLPG hisseleri i\u00e7in 2025-2030 fiyat tahmini nedir?","answer":"2025 sonunda 32-36 $, 2026'da 40-50 $, 2028'de 60-80 $ ve 2030'da 100 $ \u00fczeri hedeflenmektedir. Bu tahminler klinik geli\u015fmeler ve stratejik uygulamalara ba\u011fl\u0131d\u0131r."},{"question":"Yeni ba\u015flayanlar GLPG hisseleriyle nas\u0131l i\u015flem yapmal\u0131?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, d\u00fczenli k\u00fc\u00e7\u00fck yat\u0131r\u0131mlar yap\u0131n, fiyat uyar\u0131lar\u0131 belirleyin ve risk tolerans\u0131n\u0131za uygun pozisyon b\u00fcy\u00fckl\u00fc\u011f\u00fcn\u00fc koruyun."},{"question":"Pocket Option biyoteknoloji yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 hesap do\u011frulama ve geni\u015f \u00e7ekim se\u00e7enekleri sunarak, y\u00fcksek volatiliteye sahip biyoteknoloji hisselerinde esnek ve h\u0131zl\u0131 i\u015flem yapma imkan\u0131 sa\u011flar."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T11:11:58+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m\",\"datePublished\":\"2025-09-01T11:11:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/\",\"name\":\"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-09-01T11:11:58+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/","og_locale":"tr_TR","og_type":"article","og_title":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/","og_site_name":"Pocket Option blog","article_published_time":"2025-09-01T11:11:58+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m","datePublished":"2025-09-01T11:11:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/","name":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r - Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-09-01T11:11:58+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-galapagos-nv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Galapagos NV (GLPG) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Galapagos NV (GLPG) Hisse Senedine Yat\u0131r\u0131m"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":366940,"slug":"how-to-buy-galapagos-nv","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Galapagos NV (GLPG) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Galapagos NV (GLPG)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-galapagos-nv\/"},"pt_AA":{"locale":"pt_AA","id":366937,"slug":"how-to-buy-galapagos-nv","post_title":"Como comprar a\u00e7\u00f5es da Galapagos NV (GLPG) - Investimento em a\u00e7\u00f5es da Galapagos NV (GLPG)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-galapagos-nv\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/366939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=366939"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/366939\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=366939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=366939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=366939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}